Equillium Inc (EQ) Stock Analysis
Verdict: HOLD
Phase III de-risking and aggressive analyst re-ratings drive momentum, but 12-month cash runway necessitates near-term capital discipline.
Investment score: 64/100
Analysis as of
Is Equillium Inc stock worth reviewing? AI model thesis
Equillium is exhibiting a classic clinical-stage breakout fueled by massive analyst price target hikes and positive earnings surprises. While the cash burn is significant, the current balance sheet and Phase III pipeline progress justify the current momentum.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 78/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Equillium Inc opportunities and risks
What speaks for EQ
- Phase III Itolizumab Catalyst
What speaks against EQ
- Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| EQ | n/a | 0.0x | n/a | 0.0% | 0.0% | -18.4% |
| ANIK | n/a | 1.7x | n/a | 58.6% | -9.5% | 0.5% |
| TNYA | n/a | 643.5x | n/a | 144.9% | -36891.1% | -44.6% |
| UNCY | n/a | 0.0x | n/a | 0.0% | 0.0% | -18.1% |
| ABOS | n/a | 0.0x | n/a | 0.0% | 0.0% | -67.0% |
| QTTB | 4.7x | 2.6x | 4.6x | 99.5% | 61.9% | -19.4% |
| Peer median | n/a | 1.7x | n/a | 58.6% | 0.0% | -19.4% |
Frequently asked questions about Equillium Inc (EQ)
Is EQ stock a good investment?
The cached TradeMates AI model rates Equillium Inc as HOLD with an investment score of 64/100. Equillium is exhibiting a classic clinical-stage breakout fueled by massive analyst price target hikes and positive earnings surprises. While the cash burn is significant, the current balance sheet and Phase III pipeline progress justify the current momentum. This is algorithmic model output, not personal investment advice.
Is EQ stock a buy?
The TradeMates model verdict for EQ is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.